Article
Transcutaneous delivery of disease specific PI3K/Akt/mTOR inhibitor based hybrid…
medRxiv · 2024 · keshari, R.; Bagale, R.; Rath, S.; De, A.; Banerjee, R.; Sen, S.; Srivastava, R.
Key facts
| Title | Transcutaneous delivery of disease specific PI3K/Akt/mTOR inhibitor based hybrid nanoparticles in hydrogel system for the management of psoriasis: Insights from in vivo studies |
|---|---|
| First author | keshari, R.; Bagale, R.; Rath, S.; De, A.; Banerjee, R.; Sen, S.; Srivastava, R. |
| Journal | medRxiv |
| Published | Jan 1, 2024 |
| DOI | 10.1101/2024.06.17.599287 |
| Devices mentioned | K790117, K800552, K853723, K860811, K862004, K874160, K874609, K912581, K915561, K915840, K920529, K920967 and 11 more |
| Product codes mentioned | EPT, GCJ, GCT, GEX, HET, HJO, HLI, HLQ, HQF, JXR, KKX |
At a glance
- 10–99 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1